Loading stock data…
EVMN
$24.50+0.70 (+2.94%)
Market ClosedLast close May 1
Evommune, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.50
Potential Upside
5%
Whystock Fair Value$25.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$51.57+110.5%
Range$48.00 – $55.00
Fundamentals
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneou...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$976.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.50%
Volume
Today's trading volume
310,045
Recent News
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says
Evommune's (EVMN) experimental drug for chronic hives may have broader uses if upcoming trial result
Biotech’s IPO comeback; Trump’s tariff loophole for pharma
Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tariffs.
Evommune bucked biotech IPO drought and is focused on the long game
Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win.
Apogee strengthens case for longer-lasting eczema drug
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.
Evommune Stock Sees RS Rating Rise To 91
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.